Regulatory Considerations for Stability Studies of Co-Processed Active Pharmaceutical Ingredient

Area of Science:

• Pharmaceutical Science
• Drug Development
• Regulatory Affairs

Background:

• Co-processed active pharmaceutical ingredients (CP API) combine APIs with excipients for enhanced properties.
• Current regulatory classification of CP APIs as either APIs or drug product intermediates creates ambiguity.
• This ambiguity impacts regulatory Chemistry, Manufacturing, and Controls (CMC) expectations, particularly for stability studies.

Purpose of the Study:

• To propose clear regulatory requirements for stability studies of CP APIs.
• To provide recommendations for stability testing of drug products containing CP APIs.
• To address challenges in lifecycle management of regulatory documentation for CP APIs.

Main Methods:

• The white paper presents proposals from the CP API Working Group (WG) of the International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).
• It includes considerations and recommendations for stability studies of CP APIs from various manufacturing sites and processes.
• Recommendations also cover post-approval changes for drug products incorporating CP APIs.

Main Results:

• The document aims to resolve ambiguities in regulatory expectations for CP API stability.
• It seeks to facilitate the broader application of CP API technology in the pharmaceutical industry.
• The proposals are intended to standardize stability study requirements.

Conclusions:

• Standardized regulatory guidance on stability studies is crucial for CP API technology.
• Clearer guidelines will facilitate consistent lifecycle management of regulatory documentation.
• Adoption of these proposals is expected to promote wider use of beneficial CP API formulations.